ADVENT TECHNOLOGIES HOLDINGS (ADN)

US00788A1051 - Common Stock

0.115  -0.01 (-10.71%)

After market: 0.119 +0 (+3.48%)

Fundamental Rating

3

Taking everything into account, ADN scores 3 out of 10 in our fundamental rating. ADN was compared to 86 industry peers in the Electrical Equipment industry. ADN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADN is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

In the past year ADN has reported negative net income.
In the past year ADN has reported a negative cash flow from operations.
ADN had negative earnings in each of the past 5 years.
In the past 5 years ADN always reported negative operating cash flow.

1.2 Ratios

ADN has a worse Return On Assets (-168.41%) than 94.05% of its industry peers.
ADN's Return On Equity of -286.20% is on the low side compared to the rest of the industry. ADN is outperformed by 84.52% of its industry peers.
Industry RankSector Rank
ROA -168.41%
ROE -286.2%
ROIC N/A
ROA(3y)-86.59%
ROA(5y)-74.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ADN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

ADN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADN has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ADN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ADN has an Altman-Z score of -6.18. This is a bad value and indicates that ADN is not financially healthy and even has some risk of bankruptcy.
ADN's Altman-Z score of -6.18 is on the low side compared to the rest of the industry. ADN is outperformed by 85.71% of its industry peers.
ADN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.18
ROIC/WACCN/A
WACC10.78%

2.3 Liquidity

A Current Ratio of 1.84 indicates that ADN should not have too much problems paying its short term obligations.
ADN has a Current ratio (1.84) which is comparable to the rest of the industry.
ADN has a Quick Ratio of 1.84. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
ADN has a Quick ratio of 0.75. This is in the lower half of the industry: ADN underperforms 79.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 0.75

6

3. Growth

3.1 Past

ADN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -151.43%.
ADN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.59%.
ADN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 132.97% yearly.
EPS 1Y (TTM)-151.43%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q9.09%
Revenue 1Y (TTM)-39.59%
Revenue growth 3Y132.97%
Revenue growth 5YN/A
Revenue growth Q2Q-47.5%

3.2 Future

The Earnings Per Share is expected to grow by 28.64% on average over the next years. This is a very strong growth
Based on estimates for the next years, ADN will show a very strong growth in Revenue. The Revenue will grow by 121.25% on average per year.
EPS Next Y-35.4%
EPS Next 2Y40.51%
EPS Next 3Y28.64%
EPS Next 5YN/A
Revenue Next Year-79.85%
Revenue Next 2Y137.79%
Revenue Next 3Y121.25%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

1

4. Valuation

4.1 Price/Earnings Ratio

ADN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ADN's earnings are expected to grow with 28.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.51%
EPS Next 3Y28.64%

0

5. Dividend

5.1 Amount

ADN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ADVENT TECHNOLOGIES HOLDINGS

NASDAQ:ADN (5/2/2024, 7:00:00 PM)

After market: 0.119 +0 (+3.48%)

0.115

-0.01 (-10.71%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.93M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -168.41%
ROE -286.2%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.84
Quick Ratio 0.75
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-151.43%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-35.4%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-39.59%
Revenue growth 3Y132.97%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y